Chemotherapy-induced cardiotoxicity in children

References

• Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.
   PubMed Web of Science ®Google Scholar
• Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995, National Cancer Institute, SEER Program. NIH Pub; Bethesda, MD; 1999. No. 99-4649.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1033–1040.
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–1582.
   PubMed Web of Science ®Google Scholar
• Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the childhood cancer survivor study. JAMA. 2003;290(12):1583–1592.
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014;32(12):1218–1227.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525–533.
   PubMed Web of Science ®Google Scholar
• Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer. 2005;44(7):600–606.
   PubMed Web of Science ®Google Scholar
• Franco VI, Henkel JM, Miller TL, et al. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract. 2011;2011:134679.
   PubMedGoogle Scholar
• Gilladoga AC, Manuel C, Tan CT, et al. The cardiotoxicity of adriamycin and daunomycin in children. Cancer. 1976;37(2 Suppl):1070–1078.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324(12):808–815.
   PubMed Web of Science ®Google Scholar
• Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15(4):1544–1552.
   PubMed Web of Science ®Google Scholar
• Goorin AM, Chauvenet AR, Perez-Atayde AR, et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr. 1990;116(1):144–147.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332(26):1738–1743.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629–2636.
   PubMed Web of Science ®Google Scholar
• Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol. 2004;22(15):3139–3148.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol. 2012;30(10):1050–1057.
   PubMed Web of Science ®Google Scholar
• Zerra P, Cochran TR, Franco VI, et al. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies. Expert Opin Pharmacother. 2013;14(11):1497–1513.
   PubMed Web of Science ®Google Scholar
• Simbre VC, Duffy SA, Dadlani GH, et al. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs. 2005;7(3):187–202.
   PubMedGoogle Scholar
• Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266(12):1672–1677.
   PubMed Web of Science ®Google Scholar
• Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14(2):362–372.
   PubMed Web of Science ®Google Scholar
• Longhi A, Ferrari S, Bacci G, et al. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs. 2007;18(6):737–744.
   PubMed Web of Science ®Google Scholar
• Dolci A, Dominici R, Cardinale D, et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008;130(5):688–695.
   PubMed Web of Science ®Google Scholar
• Lipshultz ER, Holt GE, Ramasamy R, et al. Fertility, cardiac, and orthopedic challenges in survivors of adult and childhood sarcoma. Am Soc Clin Oncol Educ Book. 2017;37:799–806.
   PubMedGoogle Scholar
• Elbl L, Hrstkova H, Tomaskova I, et al. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. Eur J Pediatr. 2005;164(11):678–684.
   PubMed Web of Science ®Google Scholar
• Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol. 1984 Feb;2(2):112–117.
   PubMed Web of Science ®Google Scholar
• Levitt G, Anazodo A, Burch M, et al. Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? Eur J Cancer. 2009;45(17):3027–3034.
   PubMed Web of Science ®Google Scholar
• Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8(8):1039–1058.
   PubMed Web of Science ®Google Scholar
• Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16(2):545–550.
   PubMed Web of Science ®Google Scholar
• Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13(4):503–512.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Stevenson KE, O’Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia. 2010;24(2):320–334.
   PubMed Web of Science ®Google Scholar
• Sarosiek KA, Fraser C, Muthalagu N, et al. Developmental regulation of mitochondrial apoptosis by c-myc governs age- and tissue-specific sensitivity to cancer therapeutics. Cancer Cell. 2017;31(1):142–156.
   PubMed Web of Science ®Google Scholar
• Fulbright JM. Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract. 2011;2011:1–9.
   Google Scholar
• Hutchins KK, Siddeek H, Franco VI, et al. Prevention of cardiotoxicity among survivors of childhood cancer. Br J Clin Pharmacol. 2017;83(3):455–465.
   PubMed Web of Science ®Google Scholar
• Lebrecht D, Setzer B, Ketelsen UP, et al. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation. 2003;108(19):2423–2429.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.
   PubMed Web of Science ®Google Scholar
• Horenstein MS, Vander Heide RS, L’Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab. 2000;71(1–2):436–444.
   PubMed Web of Science ®Google Scholar
• Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26(22):3777–3784.
   PubMed Web of Science ®Google Scholar
• Nicolay K, van der Neut R, Fok JJ, et al. Effects of adriamycin on lipid polymorphism in cardiolipin-containing model and mitochondrial membranes. Biochim Biophys Acta. 1985;819(1):55–65.
   PubMed Web of Science ®Google Scholar
• Leonard RC, Williams S, Tulpule A, et al. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast. 2009;18(4):218–224.
   PubMed Web of Science ®Google Scholar
• Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980;65(1):128–135.
   PubMed Web of Science ®Google Scholar
• Simunek T, Sterba M, Popelova O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61(1):154–171.
   PubMed Web of Science ®Google Scholar
• Chen B, Peng X, Pentassuglia L, et al. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7(2):114–121.
   PubMed Web of Science ®Google Scholar
• Ito H, Miller SC, Billingham ME, et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA. 1990;87(11):4275–4279.
   PubMed Web of Science ®Google Scholar
• Tokarska-Schlattner M, Zaugg M, Zuppinger C, et al. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol. 2006;41(3):389–405.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–1642.
   PubMed Web of Science ®Google Scholar
• Khiati S, Dalla Rosa I, Sourbier C, et al. Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clin Cancer Res. 2014;20(18):4873–4881.
   PubMed Web of Science ®Google Scholar
• Lenčová-Popelová O, Jirkovský E, Jansová H, et al. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: comparison with dexrazoxane. J Mol Cell Cardiol. 2016 Feb;29(91):92–103.
   Web of Science ®Google Scholar
• Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014 Feb 3;124(2):617–630.
   PubMed Web of Science ®Google Scholar
• Martin E, Thougaard AV, Grauslund M, et al. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology. 2009 Jan 8;255(1–2):72–79.
   PubMed Web of Science ®Google Scholar
• Ong DS, Aertker RA, Clark AN, et al. Radiation-associated valvular heart disease. J Heart Valve Dis. 2013;22(6):883–892.
   PubMed Web of Science ®Google Scholar
• Vejpongsa P, Yeh ET. Topoisomerase 2beta: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 2014;95(1):45–52.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927–1995.
   PubMed Web of Science ®Google Scholar
• Giantris A, Abdurrahman L, Hinkle A, et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. 1998;27(1):53–68.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Mason JW, Billingham ME, et al. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88(2):168–175.
   PubMed Web of Science ®Google Scholar
• Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25(4 Suppl 10):72–85.
   PubMed Web of Science ®Google Scholar
• Trachtenberg BH, Landy DC, Franco VI, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol. 2011;32(3):342–353.
   PubMed Web of Science ®Google Scholar
• Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561–578.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Cochran TR, Franco VI, et al. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol. 2013;10(12):697–710.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Scully RE, Stevenson KE, et al. Hearts too small for body size after doxorubicin for childhood leukemia: Grinch syndrome. J Clin Oncol. 2014;32:10021(abstract).
   Web of Science ®Google Scholar
• Armenian SH, Gelehrter SK, Vase T, et al. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. Clin Cancer Res. 2014;20(24):6314–6323.
   PubMed Web of Science ®Google Scholar
• Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97(8):1991–1998.
   PubMed Web of Science ®Google Scholar
• Ganame J, Claus P, Uyttebroeck A, et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr. 2007;20(12):1351–1358.
   PubMed Web of Science ®Google Scholar
• Pegelow CH, Popper RW, DeWit SA, et al. Endomyocardial biopsy to monitor anthracycline therapy in children. J Clin Oncol. 1984;2:443–446.
   PubMed Web of Science ®Google Scholar
• Lenčová-Popelová O, Jirkovský E, Mazurová Y, et al. Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. PloS One. 2014 May 7;9(5):e96055.
   PubMed Web of Science ®Google Scholar
• Calleja A, Poulin F, Khorolsky C, et al. Right ventricular dysfunction in patients experiencing cardiotoxicity during breast cancer therapy. J Oncol. 2015 Aug 3;2015:1–10.
   Web of Science ®Google Scholar
• Boczar KE, Aseyev O, Sulpher J, et al. Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy. Echo Res Pract. 2016 Sep 1;3(3):79–84.
   PubMed Web of Science ®Google Scholar
• Tadic M, Cuspidi C, Hering D, et al. The influence of chemotherapy on the right ventricle: did we forget something? Clin Cardiol. 2017; doi: 10.1002/clc.22672.
   Web of Science ®Google Scholar
• Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89(5 Pt 1):942–949.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Sanders SP, Goorin AM, et al. Monitoring for anthracycline cardiotoxicity. Pediatrics. 1994;93(3):433–437.
   PubMed Web of Science ®Google Scholar
• Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics. 2008;121(2):e387–396.
   PubMed Web of Science ®Google Scholar
• Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group long-term follow-up guidelines from the Children’s Oncology Group late effects committee and nursing discipline. J Clin Oncol. 2004;22(24):4979–4990.
   PubMed Web of Science ®Google Scholar
• Wong FL, Bhatia S, Landier W, et al. Cost-effectiveness of the Children’s Oncology Group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med. 2014;160(10):672–683.
   PubMed Web of Science ®Google Scholar
• Steingart RM, Liu JE, Oeffinger KC. Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. Ann Intern Med. 2014;160(10):731–732.
   PubMed Web of Science ®Google Scholar
• Colan SD, Lipshultz SE, Sallan SE. Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer. Prog Pediatr Cardiol. 2014;36(1):7–10.
   Google Scholar
• Pudil R, Horacek JM, Strasova A, et al. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. Exp Oncol. 2008;30(2):160–162.
   PubMedGoogle Scholar
• Burdick J, Berridge B, Coatney R. Strain echocardiography combined with pharmacological stress test for early detection of anthracycline induced cardiomyopathy. J Pharmacol Toxicol Methods. 2015;73:15–20.
   PubMed Web of Science ®Google Scholar
• Mavinkurve-Groothuis AM, Marcus KA, Pourier M, et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging. 2013;14(6):562–569.
   PubMed Web of Science ®Google Scholar
• Moon TJ, Miyamoto SD, Younoszai AK, et al. Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy. Cardiol Young. 2014;24(5):854–865.
   PubMed Web of Science ®Google Scholar
• Leger K, Slone T, Lemler M, et al. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatr Blood Cancer. 2015;62(1):123–127.
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30(23):2876–2884.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30(10):1042–1049.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol. 2010;28(8):1276–1281.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20(23):4517–4522.
   PubMed Web of Science ®Google Scholar
• Van Dalen EC, Van Der Pal HJ, Bakker PJ, et al. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer. 2004;40(5):643–652.
   PubMed Web of Science ®Google Scholar
• Silber JH, Jakacki RI, Larsen RL, et al. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol. 1993;21:477–479.
   PubMedGoogle Scholar
• Lanzarini L, Bossi G, Laudisa ML, et al. Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am Heart J. 2000;140(2):315–323.
   PubMed Web of Science ®Google Scholar
• Brown TR, Vijarnsorn C, Potts J, et al. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study. Pediatr Blood Cancer. 2013;60(5):842–848.
   PubMed Web of Science ®Google Scholar
• Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.
   PubMed Web of Science ®Google Scholar
• Brouwer CA, Gietema JA, van den Berg MP, et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann Oncol. 2006;17(10):1586–1591.
   PubMed Web of Science ®Google Scholar
• Aminkeng F, Ross CJ, Rassekh SR, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82(3):683–695.
   PubMed Web of Science ®Google Scholar
• Krischer JP, Cuthbertson DD, Epstein, S, et al. Risk factors for early anthracycline cardiotoxicity in children: the Pediatric Oncology Group experience. Prog Pediatr Cardiol. 1998;8:83–90.
   Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112(24):3754–3762.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Elbared J, Drouin S, et al. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):530–535.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Kutok JL, et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013;119(19):3555–3562.
   PubMed Web of Science ®Google Scholar
• Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H: quinoneoxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112(12):2789–2795.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol. 2004;22(5):769–773.
   PubMed Web of Science ®Google Scholar
• Akam-Venkata J, Franco VI, Lipshultz SE. Late cardiotoxicity: issues for childhood cancer survivors. Curr Treat Options Cardiovasc Med. 2016;18(7):47.
   PubMedGoogle Scholar
• Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820–828.
   PubMed Web of Science ®Google Scholar
• El-Shitany NA, Tolba OA, El-Shanshory MR, et al. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail. 2012;18(8):607–613.
   PubMed Web of Science ®Google Scholar
• Nabati M, Janbabai G, Baghyari S, et al. Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol. 2017 Jan 30;69:279–285. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Herman EH, Ferrans VJ, Myers CE, et al. Comparison of the effectiveness of (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. 1985;45(1):276–281.
   PubMed Web of Science ®Google Scholar
• Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988;319(12):745–752.
   PubMed Web of Science ®Google Scholar
• Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10(1):117–127.
   PubMed Web of Science ®Google Scholar
• Tonkin K, Bates M, Lieu D, et al. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation. Can J Oncol. 1996;6(2):458–473.
   PubMedGoogle Scholar
• Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997;15(4):1333–1340.
   PubMed Web of Science ®Google Scholar
• Hochster HS. Clinical pharmacology of dexrazoxane. Semin Oncol. 1998;25(4 Suppl 10):37–42.
   PubMed Web of Science ®Google Scholar
• Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839–8846.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Neuberg DS, Stevenson KE, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011;47(9):1373–1379.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351(2):145–153.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950–961.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Devidas M, Chen L, et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol. 2016;34(8):854–862.
   PubMed Web of Science ®Google Scholar
• Kopp LM, Bernstein ML, Schwartz CL, et al. The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS). J Clin Oncol. 2012;30:15_suppl, 9503-9503
   Web of Science ®Google Scholar
• Lipshultz SE, Anderson LM, Miller TL, et al. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016;122(6):946–953.
   PubMed Web of Science ®Google Scholar
• Schwartz CL, Wexler LH, Krailo MD, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63(1):54–61.
   PubMed Web of Science ®Google Scholar
• Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25(5):493–500.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Orav EJ. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin’s disease: a claim without compelling evidence. J Clin Oncol. 2007;25(21):3179.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Stevenson KE, Franco VI, et al. Hearts too small for body size after doxorubicin for childhood ALL: Grinch syndrome. J Clin Oncol. 2014;32:10021.
   Web of Science ®Google Scholar
• Chow EJ, Asselin BL, Schwartz CL, et al. Late mortality after dexrazoxane treatment: a report from the Children’s Oncology Group. J Clin Oncol. 2015;33(24):2639–2645.
   PubMed Web of Science ®Google Scholar
• Attia SM, Ahmad SF, Bakheet SA. Impact of dexrazoxane on doxorubicin-induced aneuploidy in somatic and germinal cells of male mice. Cancer Chemother Pharmacol. 2016;77(1):27–33.
   PubMed Web of Science ®Google Scholar
• Chow EJ, Doody RD, Armenian SH, et al. Effect of dexrazoxane on heart function among long-term survivors of childhood leukemia and lymphoma: a report from the Children’s Oncology Group. ASH 58th Annual Meeting and Exposition. December 3-6, 2016; San Diego, CA;  No. 696 (abstract).
   Google Scholar
• Shaikh F, Dupuis LL, Alexander S, et al. Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis. J Natl Cancer Inst. 2016;108(4):djv357.
   PubMedGoogle Scholar
• Lipshultz SE, Franco VI, Sallan SE, et al. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence. Prog Pediatr Cardiol. 2014;36(1):39–49.
   Google Scholar
• Fulbright JM, Huh W, Anderson P, et al. Can anthracycline therapy for pediatric malignancies be less cardiotoxic? Curr Oncol Rep. 2010;12:411–419.
   PubMed Web of Science ®Google Scholar
• Safra T. Cardiac safety of liposomal anthracyclines. Oncologist. 2003;8(suppl 2):17–24.
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Wigler N, Inbar M, et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–449.
   PubMed Web of Science ®Google Scholar
• Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–1454.
   PubMed Web of Science ®Google Scholar
• Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors. Clin Cancer Res. 2002 Feb 1;8(2):413–418.
   PubMed Web of Science ®Google Scholar
• Munoz A, Maldonado M, Pardo N, et al. Pegylated liposomal doxorubicin hydrochloride (PLD) for advanced sarcomas in children: preliminary results. Pediatr Blood Cancer. 2004;43(2):152–155.
   PubMed Web of Science ®Google Scholar
• Stöhr W, Paulides M, Brecht I, et al. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS). J Cancer Res Clin Oncol. 2006;132(1):35–40.
   PubMed Web of Science ®Google Scholar
• Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10(7):1103–1111.
   PubMed Web of Science ®Google Scholar
• Shirkey H. Therapeutic orphans. J Pediatr. 1968;72(1):119–120.
   PubMed Web of Science ®Google Scholar
• Milne CP, Davis J. The pediatric studies initiative: after 15 years have we reached the limits of the law? Clin Ther. 2014;36(2):156–162.
   PubMed Web of Science ®Google Scholar
• Pasquali SK, Lam WK, Chiswell K, et al. Status of the pediatric clinical trials enterprise: an analysis of the US ClinicalTrials.gov registry. Pediatrics. 2012;130(5):e1269–1277.
   PubMed Web of Science ®Google Scholar
• Tsukamoto K, Carroll KA, Onishi T, et al. Improvement of pediatric drug development: regulatory and practical frameworks. Clin Ther. 2016;38(3):574–581.
   PubMed Web of Science ®Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–166.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Miller TL, Lipsitz SR, et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics. 2012;130(6):1003–1011.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Shelburne N, Adhikari B, Brell J, et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst. 2014;106(9):dju232.
   PubMedGoogle Scholar
• Pettit SD, Lipshultz SE, Cleeland CS, et al. Enhancing quality of life as a goal for anticancer therapeutics. Sci Transl Med. 2016;8(344):344ed9.
   PubMed Web of Science ®Google Scholar
• Yeh ET, Chang HM. Oncocardiology-past, present, and future: a review. JAMA Cardiol. 2016;1(9):1066–1072.
   PubMed Web of Science ®Google Scholar